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used to descriptively compare whether meeting the 3v
and 4v-remission criteria in a single visit (at 6 or 12
months) predicts good outcome in the second year 
(1-2y). Differences in the predictive value of PGA in the
definition of remission will be assessed by comparing
the three mutually exclusive disease states using logis-
tic regression analysis. Good outcome is defined pri-
marily by radiographic damage (no deterioration in ra-
diographic scores, whatever the instrument used in
each trial), and secondarily by functional disability
(Health Assessment Questionnaire consistently ≤0.5
and no deterioration), and their combination (“overall
good outcome”). Additional analyses will consider
longer periods over which to (concurrently) define re-
mission status and outcome (between 1-5y and 1-10y),
different cut-offs to define good radiographic outcome
(change ≤0.5, ≤3 and ≤5 in radiographic score), sus-
tained remission and the influence of treatment and
other clinical factors. 
Discussion: If 4v-remission and 4v-near-remission are
associated with a similar probability of good outcomes,
particularly regarding structural damage, the 3v-re-
mission (excluding PGA) could be adopted as the tar-
get for immunosuppressive therapy. Patients’ perspec-
tives would remain essential, but assessed separately
from disease activity, using instruments adequate to
guide adjunctive therapies. 
Systematic review registration: PROSPERO, CRD42
017057099.
Keywords: Rheumatoid arthritis; Outcome research;
Patient global assessment; Patient reported outcomes;
Disease activity; Remission; Near-remission; Radiogra -
phic damage; Function; Individual patient data meta-
-analysis.
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AbstrAct
Background: Remission is the target for management of
rheumatoid arthritis (RA) and intensification of im-
munosuppressive therapy is recommended for those
that do not achieve this status. Patient global assessment
(PGA) is the single patient reported outcome consi dered
in the American College of Rheumatology/European
League Against Rheumatism remission criteria, but its
use as target has been questioned. The primary aim of
this study is to assess whether excluding PGA from the
definition of disease remission changes the association
of disease remission with long-term radiographic da -
mage and physical function in patients with RA. 
Methods: Individual patient data meta-analysis using
data from randomized controlled trials of biological and
targeted synthetic agents, identified through Clinical-
Trials.gov and PubMed. Different remission states will
be defined: (i) 4v-remission [tender (TJC28) and
swollen (SJC28) 28-joint counts both≤1, C-reactive
protein (CRP)≤1 (mg/dl), and PGA≤1 (0-10 scale)], (ii)
4v-near-remission (TJC28≤1, SJC28≤1, CRP≤1, and
PGA>1), (iii) non-remission (TJC28>1 or SJC28>1 or
CRP>1), all mutually exclusive, and (iv) 3v-remission
(TJC28≤1, SJC28≤1, CRP≤1). Likelihood ratios will be
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IntroductIon
Disease remission or low disease activity is now a rea -
listic therapeutic target in patients with rheumatoid
arthritis (RA)1, 2. The American College of Rheumato -
logy (ACR) and the European League Against Rheuma-
tism (EULAR) proposed two alternative definitions of
remission3: one based in Boolean criteria and another
on the Simplified Disease Activity Index (SDAI). The
Boolean-based definition requires that tender 28-joint
count (TJC28), swollen 28-joint count (SJC28), 
C-Reacti ve Protein (CRP, in mg/dl), and patient glo bal
asses sment (PGA, 0–10 scale) are all ≤1. The SDAI
crite rion requires that the sum of SJC28, TJC28, PGA,
CRP and physician/observer global assessment [PhGA]
is ≤3.3. These definitions have been recommended for
use in daily care of RA2. 
PGA is the sole patient reported outcome (PRO) in-
cluded in the recommended definitions of remission,
having the same weight as other criteria1-3. Its inclusion
was justified because it represents the patient’s pers -
pective and because it proved to discriminate between
active and control intervention in clinical trials3. How-
ever, several studies4-13 have shown that PGA is not
solely influenced by RA disease activity, but also by so-
ciodemographic features, geographic area, and cultu -
ral and ethnic aspects, reflecting the fact that PGA
scores can be influenced by physical and psychologi-
cal factors (including disease perception), comorbidi-
ties and fibromyalgia, among others12.
Patients that fail only one of the four Boolean criteria
have been called “near-misses”14 or “near-remission” (de -
signation applied when PGA is the solely criteria >1)13.
Previous studies4,13-15 demonstrated that the propor-
tion of near-remission patients could vary from 14.4%
up to 38.2%13, which can represent up to four times
the proportion of patients in remission13. Following
current treatment guidelines1,16 this state of near-re-
mission would justify intensification of immuno -
suppressive treatment if based on a shared decision
between patient and rheumatologist, taking structural
damage, comorbidities or contraindications into 
account (Overarching Principles A and B)2. 
The importance of incorporating PROs in the ove -
rall management plan is indisputable. However,
whether PGA conveys information that should be ta -
ken into account when considering changing im-
munosuppressive regimens in patients that have other -
wise achieved a remission state based on TJC, SJC and
CRP remains unclear. A recent study from our group12
showed that PGA was weakly correlated with “more”
objective disease activity measures (SJC28, TJC28,
CRP) but the correlations were strong with pain, fa-
tigue, function, comorbidities, depression and anxie -
ty, and were also significant with other dimensions
such as happiness and personality dimensions (weak
correlations). Furthermore, it was shown that PGA cor-
relations differ according to disease activity state, with
pain, function and joint counts having stronger corre-
lation with PGA when patients are in non-remission.
Immunosuppressive therapy, including biologic di -
sease modifying antirheumatic drugs (bDMARDs), has
been shown to improve PGA as disease activity evolves
towards remission. However, in cases where PGA is
being mainly driven by factors not related to RA,
immu nosuppressive therapy may not be able to lower
PGA ≤1, despite SJC, TJC and CRP scores ≤1 having
already been achieved. From this stage onwards, PGA
is not dependent on disease activity and the inability
to improve it further should not be interpreted as a
failure of the immunosuppressive therapy.
Progression of joint damage is one of the most im-
portant outcome measures in RA, because it reflects
historic disease activity, is associated with decline of
physical function over time, and can be reliably asses -
sed17. A recent systematic literature review (SLR)18
inves tigated the clinical predictors of radiographic pro-
gression in RA, including disease activity indices and
their individual components. Regarding the indivi dual
components, only SJC and acute phase reactants were
associated with radiographic progression. Regarding
PGA, the authors concluded that “published data for
GH [patient’s general health], PGA and EGA [evalua-
tor’s global assessment] are limited and do not support
their use as unique tools related to progression of joint
damage”18. The data analysed included two rando -
mized controlled trials (RCTs) and two prospective co-
horts, with 1 to 3 years of follow-up, including pa-
tients receiving conventional synthetic (cs)DMARDS.
However, radiographic progression may be different
in patients receiving bDMARDs. A subsequent obser-
vational study19 with 527 patients with early RA,
follow ed for 8 years, demonstrated that 31% of pa-
tients reaching  remission according to the ACR/EU-
LAR Boolean criteria, at 1, 2, 5, and 8 years (sustained
remission) had radiographic progression (>1 unit/
/year). There was no significant contribution of PGA to
the prediction of radiographic progression19. 
These observations suggest that the concept of
“disea se remission” should not include PGA for the
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necrosis factor (TNF) inhibitors; Interleukin (IL) inhi -
bitors; B-cell inhibitors; and T-cell inhibitors] or 
tsDMARD [janus kinase (JAK) inhibitors] will be in-
cluded. All routes of drug administration will be con-
sidered. Studies testing DMARDs dose spacing or sus-
pension will be excluded. 
Types of assessments 
As a minimum, studies will need to have assessed
SJC28, TJC28, CRP, and PGA (in order to determine
the Boolean-based criteria) at baseline and at 6 and 12
months and the radiographic damage assessment and
physical function at baseline, 12 and 24 months. 
IdEntIfyInG studIEs
Studies of interest were searched by one researcher
(RF), between November and December of 2016, from
the ClinicalTrials.gov registry. The following search
strategy was used, without limits: “Rheumatoid arthri-
tis” AND (“radiographic damage” OR “radiographic
progression” OR “joint damage”). A second search was
also performed in PubMed MEDLINE, for the same
time-period, using also the pharmacological names of
bDMARDs and tsDMARD as search terms. Additional-
ly, local medical contacts of pharmaceutical companies
were approached in order to identify possible pu -
blished studies missed in previous searches and how to
get access to their IPD. A summary table with the re-
sults of this search is presented in Appendix 2. 
study sElEctIon ProcEss
Full papers of the identified studies were obtained and
checked against the inclusion criteria by two re-
searchers (RF and JAPS) independently.
dAtA collEctIon ProcEssEs
Not all published studies have IPD available, which can
be the case if patients did not give permission for broa -
der research than the original study. The timing of data
availability after study publication may also vary accor -
ding to data holder policy23: while some companies
make the data available immediately after the first pu -
blication, others only do it after the investigational
product has been approved for use in both the United
States and European Union. Thus, after study selection
(Appendix 2) a research proposal was submitted to all
sponsors of those trials, asking for IPD access. 
dAtA ItEMs
In addition to the radiographic damage score and
purposes of guiding immunosuppressive therapy. Such
a definition of remission, i.e. excluding PGA from ACR/
/EULAR Boolean definition, might be designated as “re-
mission 3 variables” or “3v-remission”. Long-term lon-
gitudinal studies, looking at more objective outcomes
are required to support this change in the definition of
remission.
The primary aim of this study is to assess whether
excluding PGA from the definition of disease remission
changes the association of disease remission with long-
term radiographic damage and physical function in pa-
tients with RA. 
MEtHods/dEsIGn
This is an individual patient data (IPD) meta-analysis
of published RCTs selected from a systematic literature
search. 
Protocol And rEGIstrAtIon
This study protocol was registered in PROSPERO with
the number CRD42017057099.20 The results will be
reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses of Individual
Participant Data (PRISMA-IPD), and this checklist 
(Appendix 1) also served as guidance for writing this
protocol. 
Ethical approval to this study was granted by the
Centro Hospitalar e Universitário de Coimbra Ethics
Committee (CHUC-047-17). 
ElIGIbIlIty crItErIA
Type of studies
This study will include recently published RCTs, and
their long-term extensions (≥ 2 years), which evaluate
the efficacy of csDMARDs, bDMARDs or targeted syn-
thetic (ts) DMARD on radiographic damage in patients
with RA. 
All RCTs assessing radiographic damage assess also
physical function as a secondary outcome. Studies with
less than two years of follow-up will be excluded.
Participants
Both men and women with diagnosis of RA, and ful-
filling the 1987 ACR criteria or the 2010 ACR-EULAR
criteria for RA 21, 22, will be included. 
Types of interventions
Studies testing the efficacy of any bDMARD [Tumor
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physi cal function (outcomes), and to SJC28, TJC28,
CRP, and PGA (for remission definition) the following
varia bles will be extracted from the trials: (i) patient
characteristics – gender, age at baseline; (ii) clinical
characteristics – disease duration at baseline, rheuma-
toid factor (RF) status, anti-citrullinated peptide
antibo dy (ACPA) status, and treatment arm (iii) trial/vi -
sit information variables, namely anonymised patient
identification (ID) code, visit number or sequence, and
visit date. Appen dix 3 provides a list off all essential
variables that will be extracted from each trial.
IPd IntEGrIty
Any important issues identified when checking IPD,
such as data plausibility, consistency, completeness or
baseline imbalance will be reported and summarised
using a PRISMA-IPD flow diagram. 
rIsk of bIAs AssEssMEnt of IndIvIduAl
studIEs
The quality and potential bias of included studies will
be assessed using the guidelines for assessing quality in
prognostic studies, assigning an overall quality score
per study of between 0 and 6 points according to Hay-
den et al.24 The six topics assessed are: study participa-
tion, study attrition, prognostic factor measurement,
outcome measurement, confounding measurement
and account, and analysis. Of particular relevance for
this study will be the assessment of radiographic dama -
ge. A list of ten possible biases in the assessment of ra-
diographic data was described by van der Heijde25 and
this information will be collected separately for quali-
ty assessment of the radiographic outcome, but will not
be used as the basis for including/excluding studies.
sPEcIfIcAtIon of outcoMEs And EffEct 
MEAsurEs
For the purposes of this study the methodology adopt-
ed by the ACR/EULAR group3 to define good outcome
in radiographic damage and function (separately and
combined) will be adopted. Using the same definitions
will allow direct comparisons of the results/conclusion.
However, in the present study different definitions of
“good radiographic outcome” will be evaluated (for
more details please see “Exploration in variation effects
(sensitivity analyses)” section).
Primary outcome:
a) Percentage of individuals with a good radiographic
outcome during the second year of the trial (i.e. be-
tween month 12 and month 24).
“Good radiographic outcome” is defined as stable
radiographic scores (change ≤0 in Sharp26 or modified
Sharp scores27-29 during the second year of the trial). 
Secondary outcomes:
b) Percentage of individuals with a good functional out-
come during the second year of the trial.
“Good physical function outcome” is defined as sta-
ble and low scores of Health Assessment Questionnaire
(HAQ)30 (change ≤0 and HAQ score consistently ≤0.5
during the second year of the trial).
c) Percentage of individuals with overall good outcome
during the second year of the trial.
“Overall good outcome” is considered the combi-
nation of “good radiographic outcome” and “good
physical function outcome”. 
Additional secondary outcomes:
The above-mentioned outcomes assessed the stabili ty
between 1 and 2 years. Additional secondary outcomes
will assess stability between 1 and 5 years and between
1 and 10 years after baseline for a), b) and c), in trials
with such long follow-up. 
Measures of association:
The principal effect measure for all outcomes will be the
positive (LR+) and negative likelihood ratios (LR-).
coMPArIsons: dEfInItIons of rEMIssIon 
Analyses will be based on the definition of different re-
mission states (Figure 1), assessed at 6 months and 12
months, following the methodology adopted by the
ACR/EULAR committee3, as follows:
a) ACR/EULAR Boolean-based remission3, also de-
signed in this project as “4v-Remission” (i.e.,
TJC28≤1, SJC28≤1, CRP mg/dl ≤1, and PGA≤1/10) 
b) “4v-near-remission”13, 14, defined as TJC28≤1,
SJC28≤1, CRP mg/dl ≤1, and PGA>1. 
c) “Non-remission” defined as TJC28>1 or SJC28>1 or
CRP mg/dl >1.
The above three definitions are mutually exclusive,
i.e. each patient will be categorized in one group only. 
d) “3v-remission” defined as TJC28≤1, SJC28≤1, CRP
mg/dl ≤1.
All remission definitions are considered to be satis-
fied when they are satisfied either at 6 or 12 months
follow-up.
The LR for good outcome associated with 4v and 3v-
-remission states will be descriptively compared. Then,
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e.g. when they satisfy both the 4v-remission and 4v-
-near-remission definitions at two consecutive visits,
or have both a ConRew score >25th percentile based on
4v-remission and 4v-near remission, they are assigned
to the 4v remission category.
dAtA AnAlysIs And syntHEsIs
Data analysis
To guarantee privacy and security of IPD, the platforms
in which the data is available require that statistics be
performed via remote and secure online platforms,
which impedes data download. However, all platforms
commonly allow the use of SAS software, which will be
used within each platform. For data synthesis Stata
software, version 14 will be used. Thus the same pro-
cedures will need to be performed in each platform. 
Means and standard deviations (SD) will be used to
describe normally distributed continuous data, medians
and interquartile ranges to describe continuous data
that are not normally distributed, and frequencies and
percentages will be used for categorical data. Data will
be described using 95% confidence intervals (95% CI). 
The number of true positive (TP), true negative
(TN), false negative (FN) and false positive (FP) statis-
tics will be extracted for each dataset. Then, sensitivi-
ty, specificity, positive and negative predictive value
(PPV and NPV) will be determined for being in (sus-
tained) remission (by 3v and 4v-remission) to predict
good radiographic outcome at 2-years after baseline.
The LR+ and LR- will then be calculated by the for-
mulas: sensitivity/(1-specificity) and (1-sensitivity)/speci-
ficity, respectively. All analyses will be repeated for se -
condary outcomes: good function, and overall good
outcome. 
LRs, calculated as above, will be descriptively com-
pared. In a second phase, participants in non-remission
will be excluded from analyses and LRs for good radio-
graphic outcome will be calculated for “4v-remission”
versus “4v-near-remission”, as a means to assess the pre-
dictive impact of PGA (Appendix 4, image C). 
To additionally test the predictive value of PGA in
the definition of remission, logistic regression will be
used with the outcome of interest - radiographic sta-
bility - as dependent variable. The independent vari-
ables will include remission (a categorical variable in-
dicating whether a patient is in “4v-remission”,
“4v-near-remission”, or not satisfying any of these def-
initions, i.e. “non-remission”) (Appendix 4, images D
and E). The regression coefficient/odds ratio (OR) (and
95% CI) comparing the “4v-near-remission” category
an analysis will be performed for evaluating the (lack
of) additional predictive value of PGA in the definition
of remission, using the mutually exclusive categories
(“4v-remission”, “4v-near-remission” and “non-re -
mission”) (for more details please see “data analyses”
section and Appendix 4). 
dEfInItIons of sustAInEd rEMIssIon
Sensitivity analyses will assess the influence of sus-
tained remission, i.e. remission in more than a single
time-point (6 or 12 months), in the prediction of good
outcomes in RA. Because there is no currently uniform
definition of sustained remission, the following will be
tested: (i) remission at 6 and 12 months, (ii) remission
at two consecutive visits among all time-points consis-
tently available during the first year in all trials, ideal-
ly separated by 3 months (i.e. 3, 6, 9, and 12 months),
as suggested by Konijn et al.31, (iii) having or not ≥50%
of visits in remission, and (iv) using the “Continuity
Reward” (ConRew) score proposed by Boers et al.32,
which gives 1 point for a period in remission and a
bonus (1 point more) if the subsequent period is also
remission or if it is the last observation period. Because
ConRew is a continuous score and the distributions are
expected to be strongly right skewed32, the 25th per-
centile will be considered as cut-off to dichotomize sus-
tained versus non-sustained remission. Definitions (iii)
and (iv) will consider the visits from the beginning to
the end of the follow-up under consideration, i.e. not
only the first year of the trial and patients will be clas-
sified to the ‘highest category’ for definitions ii an iv,
fIGurE 1. Definitions of Boolean remission considered for this
study, adapted from the ACR/EULAR Boolean definition
CRP: C-reactive protein, PGA: patien global assessment; 
SJC28: swollen 28-joint counts; TJC28: tender 28-joint counts
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with the “4v-remission” category will indicate whether
there is any relevant difference between these groups
and thus whether PGA has any additional predictive
value for outcome.
Missing data will not be submitted to any method of
data imputation, based on the comparable results of im-
puted and non-imputed data shown by a similar analy -
sis31. The number and percentage of patients with miss-
ing values for each variable will be reported per trial. 
Measures to adjust for confounders
In order to adjust for important covariates (gender, age
at baseline, disease duration at baseline, RF, ACPA, ra-
diographic damage at baseline, treatment arm), logistic
regression (as above) will be used in individual studies.
Data synthesis
A two-step approach will be followed in this IPD meta-
-analysis. Thus, the TP, TN, FN, and FP results obtained
for each trial in a first step (described above) will be
used to synthetize the data in a second step. To consider
the results from the mutually exclusive definitions of re-
mission and to take into account the influence of the
covariates, the OR and its standard error (SE) resulting
from the logistic regression will also be synthesized,
using appropriate fixed-effect and random-effects
approa ches, as suggested by Chang and Hoaglin33.
As the definitions of remission will be the same over
all studies as well as the definition of the outcome (as
they are calculated by the authors), a Bivariate hierar-
chical model with random effect will be used to sum-
marize the diagnostic association measure34.
The I2 of Higgins and Thompson will be calculated
to quantify heterogeneity35,36.
ExPlorAtIon In vArIAtIon EffEcts 
(sEnsItIvIty AnAlysEs)
In recent years a statistically significant reduction in ra-
diographic progression during clinical studies in pa-
tients with RA has become difficult to detect due to ear-
ly-escape study designs and to declining rates of
progression in control-group patients37. For this rea-
son, and also to be consistent with the methodology
used by ACR and EULAR to establish the current defi -
nition of remission, a strict definition of good outcome
was adopted for this study, i.e, a change ≤0 in radiogra -
phic progression. However, the majority of recent stu -
dies consider a cut-off ≤0.5 to define radiographic sta-
bility, to allow for a maximum change of 1 unit by one
of the two readers. Therefore, a sensitivity analysis will
consider change ≤0.5 units as cut-off for radiographic
da mage progression. Also, in order to account for in-
ter and intra-rater variation of the radiographic
score31,38,39 and to provide information on the magni-
tude of structural damage, two additional cut-offs to
define good radiographic outcome will be considered:
≤3 and ≤5 units of the radiographic score. It is also ar-
gued that the number of years of follow-up could affect
the results of radiographic outcomes19. Thus, in addi-
tion to the main analysis of the 2-year outcome (the
most frequently reported), outcomes at 5 and 10 years
after baseline will also be assessed, i.e, 4 and 9 years’
stabili ty after 12 months. 
The definition of “sustained” remission (and non-
-remission) based on only 1 time point or even 2 con-
secutive time points may not fully capture all relevant
information32. Thus we will explore whether multiple
remission and relapse periods are related to long-term
radiographic progression and compare the perfor-
mance of 3v and 4v-remission definitions, namely 
using the ConRew score32, as explained above.
We will, finally, evaluate whether the relationship
between the definition of remission and outcome is af-
fected by treatment (mono versus combined), disease
duration (early versus established), and history of pre-
vious DMARD treatments (naive versus failure/non-res -
ponders).
dIscussIon
This study will evaluate whether the predictive value of
3v and 4v-remission states regarding the development
of structural damage, are comparable. If confirmed, the
inclusion of PGA in the definition of remission as treat-
ment target should be revised (to 3v-remission), thus
helping to avoid unnecessary immunosuppressive
treatment escalation and associated risks. Given that
more patients attain 3v than 4v-remission, it is expect-
ed that the value (long term benefit) of available the -
rapies will be reassessed and probably recognized as
higher than previously acknowledged. 
If no relevant difference is observed by including or
excluding PGA from the definition, the proposal to-
wards the adoption of two separate targets for the treat-
ment of RA of therapy (control of the disease process
and control of its impact upon the patient’s life) will be
strongly supported.  Disease impact will continue to
be core to the assessment and management of the disea -
se but it will be better served by instruments that allow
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the health professionals to understand the reasons dri -
ving a high-perceived impact of the disease. Once di -
sease control is achieved, adjunctive pharmacological
and non-pharmacological therapies of different nature
may be considered, based on the understanding of
disea se impact in the individual patient12,13. 
In case the results demonstrate that including PGA
in the ACR/EULAR Boolean-based definition increases
its predictive value of good outcomes, the current defi -
nition of remission is supported. This would not in-
validate the need to consider a separate patient impact
target40,41. We would argue, in any case, following
availa ble evidence, that the formulation of PGA should
be standardized42,43 and that patients should have a
dedicated debriefing about this measure in order to im-
prove its reliability44. 
An IPD meta-analysis is adequate for this study be-
cause it allows calculating a new definition of remission
in RA, the 3v-remission that includes the same varia -
bles used to assess remission by current definitions. Be-
ing “new”, this definition has never been published, thus
not accessible through a conventional meta-analy sis. 
This type of meta-analysis has many advantages but
also some limitations.45-47 The main advantages of this
specific study include access: (i) to large datasets of pa-
tients, (ii) with long-term outcome assessment, and (iii)
rigorous data collection. The potential limitations are
mainly related with the different designs of the RCTs in-
cluded, namely: different inclusion criteria (e.g. pa-
tients naive versus non-responders to MTX), different
treatments (e.g. patient in mono versus combined
DMARD therapy), different time point assessments
within the same period, or variation in radiographic
scoring. To face these limitations different sub-group
and sensitivity analyses are planned, that will allow
guaranteeing the rigor and generalizability of the re-
sults. The inclusion of highly experienced experts in
radiographic outcome assessment and in RCT design,
development, and statistical analyses in this interna-
tional consortium of researchers will also contribute to
overcome possible difficulties. All the authors will be
engaged in close critical appraisal in every step of the
analyses to ensure the validity of the results and con-
clusions of this study. To guarantee quality control and
reproducibility of the procedures the analysis’s syntax
will be recorded.  
Two important decisions that were taken during
study design are important to highlight. The first deci-
sion was regarding the number of studies to include.
Usually, turning large amounts of data into actionable
information allows better contributions in epidemiolo -
gy48. The authors agreed that there was no need to in-
clude all existing RCTs testing biological and targeted
synthetic agents, but including data from different data-
-holders would strengthen this study. The second de-
cision was related with the fact that this study is ques-
tioning the current ACR/EULAR Boolean-based
definition of remission and how strictly should this
study reproduce their methodological decisions. It was
decided to reproduce their analysis but performing fur-
ther sensitivity analysis using other methodological 
options. An example was the additional cut-off for the
definition of good radiographic outcomes. Another 
example was the definition of sustained remission: al-
though ACR/EULAR committee3 have used a single
point in time (6 or 12 months) to define remission and
despite the nonexistence of a uniform definition of
sustai ned remission31, this study will also use four addi -
tional definitions.
The present study considers radiographic score as
primary endpoints and function (HAQ) and overall out-
comes as secondary endpoints. This decision was based
on the fact that HAQ: (i) is not only an outcome mea-
sure (cumulative functional deterioration over time) but
also a disease activity-related measure (impact of current
disease activity on function a specific point in time)49,
and (ii) is subjective50,51, i.e. does not measure func-
tioning of patients, but assesses their opinion on their
functioning. So, the factors underlying an unjustifiably
high PGA would be expected to have a similar effect
upon HAQ, confounding the argument. 
At the time of submission of this manuscript, all the
five pharmaceutical companies (MSD/JANSSEN, Pfi -
zer, Abbvie, Roche and UCB) contacted had already
granted us access to their RCTs, which demonstrates
the perceived value of this research project. These posi -
tive answers also assure that structural damage and
functional outcomes after 5 and 10-years of DMARD
initiation will also be possible to be compared.
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ta
 
in
de
pe
n
de
n
tl
y 
in
 d
u
pl
ic
at
e)
 a
n
d 
an
y 
pr
oc
es
se
s 
fo
r 
ob
ta
in
in
g 
an
d 
co
n
fi
rm
in
g 
th
es
e 
da
ta
 w
it
h
 i
n
ve
st
ig
at
or
s.
D
at
a 
it
em
s
11
D
es
cr
ib
e 
h
ow
 t
h
e 
in
fo
rm
at
io
n
 a
n
d 
va
ri
ab
le
s 
to
 b
e 
co
ll
ec
te
d 
w
er
e 
ch
os
en
. L
is
t 
an
d 
de
fi
n
e 
al
l 
st
u
dy
 l
ev
el
 a
n
d 
pa
rt
ic
ip
an
t 
le
ve
l 
da
ta
 t
h
at
 w
er
e 
so
u
gh
t,
 i
n
cl
u
di
n
g 
ba
se
li
n
e 
an
d 
fo
ll
ow
-u
p 
in
fo
rm
at
io
n
. I
f 
ap
pl
ic
ab
le
, d
es
cr
ib
e 
m
et
h
od
s 
of
 s
ta
n
da
rd
is
in
g 
or
 
tr
an
sl
at
in
g 
va
ri
ab
le
s 
w
it
h
in
 t
h
e 
IP
D
 d
at
as
et
s 
to
 e
n
su
re
 c
om
m
on
 s
ca
le
s 
or
 m
ea
su
re
m
en
ts
 a
cr
os
s 
st
u
di
es
.
IP
D
 i
n
te
gr
it
y
A
1
D
es
cr
ib
e 
w
h
at
 a
sp
ec
ts
 o
f 
IP
D
 w
er
e 
su
bj
ec
t 
to
 d
at
a 
ch
ec
ki
n
g 
(s
u
ch
 a
s 
se
qu
en
ce
 g
en
er
at
io
n
, d
at
a 
co
n
si
st
en
cy
 a
n
d 
co
m
pl
et
en
es
s,
 
ba
se
li
n
e 
im
ba
la
n
ce
) 
an
d 
h
ow
 t
h
is
 w
as
 d
on
e.
R
is
k 
of
 b
ia
s 
12
D
es
cr
ib
e 
m
et
h
od
s 
u
se
d 
to
 a
ss
es
s 
ri
sk
 o
f 
bi
as
 i
n
 t
h
e 
in
di
vi
du
al
 s
tu
di
es
 a
n
d 
w
h
et
h
er
 t
h
is
 w
as
 a
pp
li
ed
 s
ep
ar
at
el
y 
fo
r 
as
se
ss
m
en
t 
in
 
ea
ch
 o
u
tc
om
e.
 I
f 
ap
pl
ic
ab
le
, d
es
cr
ib
e 
h
ow
 f
in
di
n
gs
 o
f 
IP
D
 c
h
ec
ki
n
g 
w
er
e 
u
se
d 
to
 i
n
fo
rm
 t
h
e 
as
se
ss
m
en
t.
 
in
di
vi
du
al
 
R
ep
or
t 
if
 a
n
d 
h
ow
 r
is
k 
of
 b
ia
s 
as
se
ss
m
en
t 
w
as
 u
se
d 
in
 a
n
y 
da
ta
 s
yn
th
es
is
.  
st
u
di
es
.
Sp
ec
if
ic
at
io
n
 
13
St
at
e 
al
l 
tr
ea
tm
en
t 
co
m
pa
ri
so
n
s 
of
 i
n
te
re
st
s.
 S
ta
te
 a
ll
 o
u
tc
om
es
 a
dd
re
ss
ed
 a
n
d 
de
fi
n
e 
th
em
 i
n
 d
et
ai
l. 
of
 o
u
tc
om
es
 
St
at
e 
w
h
et
h
er
 t
h
ey
 w
er
e 
pr
e-
sp
ec
if
ie
d 
fo
r 
th
e 
re
vi
ew
 a
n
d,
 i
f 
ap
pl
ic
ab
le
, w
h
et
h
er
 t
h
ey
 w
er
e 
pr
im
ar
y/
m
ai
n
 o
r 
an
d 
ef
fe
ct
 
se
co
n
da
ry
/a
dd
it
io
n
al
 o
u
tc
om
es
. G
iv
e 
th
e 
pr
in
ci
pa
l 
m
ea
su
re
s 
of
 e
ff
ec
t 
(s
u
ch
 a
s 
ri
sk
 r
at
io
, h
az
ar
d 
ra
ti
o,
 d
if
fe
re
n
ce
m
ea
su
re
s
in
 m
ea
n
s)
 u
se
d 
fo
r 
ea
ch
 o
u
tc
om
e.
Sy
n
th
es
is
 
14
D
es
cr
ib
e 
th
e 
m
et
a-
an
al
ys
is
 m
et
h
od
s 
u
se
d 
to
 s
yn
th
es
is
e 
IP
D
. S
pe
ci
fy
 a
n
y 
st
at
is
ti
ca
l 
m
et
h
od
s 
an
d 
m
od
el
s 
u
se
d.
 
m
et
h
od
s 
Is
su
es
 s
h
ou
ld
 i
n
cl
u
de
 (
bu
t 
ar
e 
n
ot
 r
es
tr
ic
te
d 
to
):
•
U
se
 o
f 
a 
on
e-
st
ag
e 
or
 t
w
o-
st
ag
e 
ap
pr
oa
ch
.
•
H
ow
 e
ff
ec
t 
es
ti
m
at
es
 w
er
e 
ge
n
er
at
ed
 s
ep
ar
at
el
y 
w
it
h
in
 e
ac
h
 s
tu
dy
 a
n
d 
co
m
bi
n
ed
 a
cr
os
s 
st
u
di
es
 (
w
h
er
e 
ap
pl
ic
ab
le
).
•
Sp
ec
if
ic
at
io
n
 o
f 
on
e-
st
ag
e 
m
od
el
s 
(w
h
er
e 
ap
pl
ic
ab
le
) 
in
cl
u
di
n
g 
h
ow
 c
lu
st
er
in
g 
of
 p
at
ie
n
ts
 w
it
h
in
 s
tu
di
es
 w
as
 a
cc
ou
n
te
d 
fo
r.
•
U
se
 o
f 
fi
xe
d 
or
 r
an
do
m
 e
ff
ec
ts
 m
od
el
s 
an
d 
an
y 
ot
h
er
 m
od
el
 a
ss
u
m
pt
io
n
s,
 s
u
ch
 a
s 
pr
op
or
ti
on
al
 h
az
ar
ds
.
•
H
ow
 (
su
m
m
ar
y)
 s
u
rv
iv
al
 c
u
rv
es
 w
er
e 
ge
n
er
at
ed
 (
w
h
er
e 
ap
pl
ic
ab
le
).
•
M
et
h
od
s 
fo
r 
qu
an
ti
fy
in
g 
st
at
is
ti
ca
l 
h
et
er
og
en
ei
ty
 (
su
ch
 a
s 
I2
 a
n
d 
τ
2)
. 
•
H
ow
 s
tu
di
es
 p
ro
vi
di
n
g 
IP
D
 a
n
d 
n
ot
 p
ro
vi
di
n
g 
IP
D
 w
er
e 
an
al
ys
ed
 t
og
et
h
er
 (
w
h
er
e 
ap
pl
ic
ab
le
).
•
H
ow
 m
is
si
n
g 
da
ta
 w
it
h
in
 t
h
e 
IP
D
 w
er
e 
de
al
t 
w
it
h
 (
w
h
er
e 
ap
pl
ic
ab
le
).
co
nt
in
ue
s 
on
 t
he
 n
ex
t 
pa
ge
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Ferreira rJO et al
c
o
n
t
In
u
A
t
Io
n
P
R
IS
M
A
-I
P
D
It
em
 
R
ep
or
te
d
 
Se
ct
io
n
/t
op
ic
N
o
C
h
ec
kl
is
t 
it
em
on
 p
ag
e
E
xp
lo
ra
ti
on
 o
f 
A
2
If
 a
pp
li
ca
bl
e,
 d
es
cr
ib
e 
an
y 
m
et
h
od
s 
u
se
d 
to
 e
xp
lo
re
 v
ar
ia
ti
on
 i
n
 e
ff
ec
ts
 b
y 
st
u
dy
 o
r 
pa
rt
ic
ip
an
t 
le
ve
l 
ch
ar
ac
te
ri
st
ic
s 
(s
u
ch
va
ri
at
io
n
 i
n
 
as
 e
st
im
at
io
n
 o
f 
in
te
ra
ct
io
n
s 
be
tw
ee
n
 e
ff
ec
t 
an
d 
co
va
ri
at
es
).
 S
ta
te
 a
ll
 p
ar
ti
ci
pa
n
t-
le
ve
l 
ch
ar
ac
te
ri
st
ic
s 
th
at
 w
er
e 
an
al
ys
ed
ef
fe
ct
s
as
 p
ot
en
ti
al
 e
ff
ec
t 
m
od
if
ie
rs
, a
n
d 
w
h
et
h
er
 t
h
es
e 
w
er
e 
pr
e-
sp
ec
if
ie
d.
R
is
k 
of
 b
ia
s 
15
Sp
ec
if
y 
an
y 
as
se
ss
m
en
t 
of
 r
is
k 
of
 b
ia
s 
re
la
ti
n
g 
to
 t
h
e 
ac
cu
m
u
la
te
d 
bo
dy
 o
f 
ev
id
en
ce
, i
n
cl
u
di
n
g 
an
y 
pe
rt
ai
n
in
g 
to
 n
ot
 o
bt
ai
n
in
g
ac
ro
ss
 s
tu
di
es
IP
D
 f
or
 p
ar
ti
cu
la
r 
st
u
di
es
, o
u
tc
om
es
 o
r 
ot
h
er
 v
ar
ia
bl
es
.
A
dd
it
io
n
al
 
16
D
es
cr
ib
e 
m
et
h
od
s 
of
 a
n
y 
ad
di
ti
on
al
 a
n
al
ys
es
, i
n
cl
u
di
n
g 
se
n
si
ti
vi
ty
 a
n
al
ys
es
. S
ta
te
 w
h
ic
h
 o
f 
th
es
e 
w
er
e 
pr
e-
sp
ec
if
ie
d.
an
al
ys
es
 
R
es
u
lt
s
St
u
dy
 s
el
ec
ti
on
 
17
G
iv
e 
n
u
m
be
rs
 o
f 
st
u
di
es
 s
cr
ee
n
ed
, a
ss
es
se
d 
fo
r 
el
ig
ib
il
it
y,
 a
n
d 
in
cl
u
de
d 
in
 t
h
e 
sy
st
em
at
ic
 r
ev
ie
w
 w
it
h
 r
ea
so
n
s 
fo
r 
ex
cl
u
si
on
s
an
d 
IP
D
 
at
 e
ac
h
 s
ta
ge
. I
n
di
ca
te
 t
h
e 
n
u
m
be
r 
of
 s
tu
di
es
 a
n
d 
pa
rt
ic
ip
an
ts
 f
or
 w
h
ic
h
 I
P
D
 w
er
e 
so
u
gh
t 
an
d 
fo
r 
w
h
ic
h
 I
P
D
 w
er
e 
ob
ta
in
ed
.
ob
ta
in
ed
F
or
 t
h
os
e 
st
u
di
es
 w
h
er
e 
IP
D
 w
er
e 
n
ot
 a
va
il
ab
le
, g
iv
e 
th
e 
n
u
m
be
rs
 o
f 
st
u
di
es
 a
n
d 
pa
rt
ic
ip
an
ts
 f
or
 w
h
ic
h
 a
gg
re
ga
te
 d
at
a 
w
er
e 
av
ai
la
bl
e.
 R
ep
or
t 
re
as
on
s 
fo
r 
n
on
-a
va
il
ab
il
it
y 
of
 I
P
D
. I
n
cl
u
de
 a
 f
lo
w
 d
ia
gr
am
.
St
u
dy
 
18
F
or
 e
ac
h
 s
tu
dy
, p
re
se
n
t 
in
fo
rm
at
io
n
 o
n
 k
ey
 s
tu
dy
 a
n
d 
pa
rt
ic
ip
an
t 
ch
ar
ac
te
ri
st
ic
s 
(s
u
ch
 a
s 
de
sc
ri
pt
io
n
 o
f 
in
te
rv
en
ti
on
s,
ch
ar
ac
te
ri
st
ic
s
n
u
m
be
rs
 o
f 
pa
rt
ic
ip
an
ts
, d
em
og
ra
ph
ic
 d
at
a,
 u
n
av
ai
la
bi
li
ty
 o
f 
ou
tc
om
es
, f
u
n
di
n
g 
so
u
rc
e,
 a
n
d 
if
 a
pp
li
ca
bl
e 
du
ra
ti
on
 o
f 
fo
ll
ow
-u
p)
. P
ro
vi
de
 (
m
ai
n
) 
ci
ta
ti
on
s 
fo
r 
ea
ch
 s
tu
dy
. W
h
er
e 
ap
pl
ic
ab
le
, a
ls
o 
re
po
rt
 s
im
il
ar
 s
tu
dy
 c
h
ar
ac
te
ri
st
ic
s 
fo
r 
an
y 
st
u
di
es
 
n
ot
 p
ro
vi
di
n
g 
IP
D
.
IP
D
 i
n
te
gr
it
y
A
3
R
ep
or
t 
an
y 
im
po
rt
an
t 
is
su
es
 i
de
n
ti
fi
ed
 i
n
 c
h
ec
ki
n
g 
IP
D
 o
r 
st
at
e 
th
at
 t
h
er
e 
w
er
e 
n
on
e.
R
is
k 
of
 b
ia
s 
19
P
re
se
n
t 
da
ta
 o
n
 r
is
k 
of
 b
ia
s 
as
se
ss
m
en
ts
. I
f 
ap
pl
ic
ab
le
, d
es
cr
ib
e 
w
h
et
h
er
 d
at
a 
ch
ec
ki
n
g 
le
d 
to
 t
h
e 
u
p-
w
ei
gh
ti
n
g 
or
 
w
it
h
in
 s
tu
di
es
do
w
n
-w
ei
gh
ti
n
g 
of
 t
h
es
e 
as
se
ss
m
en
ts
. C
on
si
de
r 
h
ow
 a
n
y 
po
te
n
ti
al
 b
ia
s 
im
pa
ct
s 
on
 t
h
e 
ro
bu
st
n
es
s 
of
 m
et
a-
an
al
ys
is
 
co
n
cl
u
si
on
s.
 
R
es
u
lt
s 
of
 
20
F
or
 e
ac
h
 c
om
pa
ri
so
n
 a
n
d 
fo
r 
ea
ch
 m
ai
n
 o
u
tc
om
e 
(b
en
ef
it
 o
r 
h
ar
m
),
 f
or
 e
ac
h
 i
n
di
vi
du
al
 s
tu
dy
 r
ep
or
t 
th
e 
n
u
m
be
r 
of
 e
li
gi
bl
e
in
di
vi
du
al
 
pa
rt
ic
ip
an
ts
 f
or
 w
h
ic
h
 d
at
a 
w
er
e 
ob
ta
in
ed
 a
n
d 
sh
ow
 s
im
pl
e 
su
m
m
ar
y 
da
ta
 f
or
 e
ac
h
 i
n
te
rv
en
ti
on
 g
ro
u
p 
(i
n
cl
u
di
n
g,
 w
h
er
e
st
u
di
es
ap
pl
ic
ab
le
, t
h
e 
n
u
m
be
r 
of
 e
ve
n
ts
),
 e
ff
ec
t 
es
ti
m
at
es
 a
n
d 
co
n
fi
de
n
ce
 i
n
te
rv
al
s.
 T
h
es
e 
m
ay
 b
e 
ta
bu
la
te
d 
or
 i
n
cl
u
de
d 
on
 a
 f
or
es
t 
pl
ot
.  
R
es
u
lt
s 
of
 
21
P
re
se
n
t 
su
m
m
ar
y 
ef
fe
ct
s 
fo
r 
ea
ch
 m
et
a-
an
al
ys
is
 u
n
de
rt
ak
en
, i
n
cl
u
di
n
g 
co
n
fi
de
n
ce
 i
n
te
rv
al
s 
an
d 
m
ea
su
re
s 
of
 s
ta
ti
st
ic
al
 
sy
n
th
es
es
h
et
er
og
en
ei
ty
. S
ta
te
 w
h
et
h
er
 t
h
e 
an
al
ys
is
 w
as
 p
re
-s
pe
ci
fi
ed
, a
n
d 
re
po
rt
 t
h
e 
n
u
m
be
rs
 o
f 
st
u
di
es
 a
n
d 
pa
rt
ic
ip
an
ts
 a
n
d,
 w
h
er
e 
ap
pl
ic
ab
le
, t
h
e 
n
u
m
be
r 
of
 e
ve
n
ts
 o
n
 w
h
ic
h
 i
t 
is
 b
as
ed
. 
W
h
en
 e
xp
lo
ri
n
g 
va
ri
at
io
n
 i
n
 e
ff
ec
ts
 d
u
e 
to
 p
at
ie
n
t 
or
 s
tu
dy
 c
h
ar
ac
te
ri
st
ic
s,
 p
re
se
n
t 
su
m
m
ar
y 
in
te
ra
ct
io
n
 e
st
im
at
es
 f
or
 e
ac
h
 
ch
ar
ac
te
ri
st
ic
 e
xa
m
in
ed
, i
n
cl
u
di
n
g 
co
n
fi
de
n
ce
 i
n
te
rv
al
s 
an
d 
m
ea
su
re
s 
of
 s
ta
ti
st
ic
al
 h
et
er
og
en
ei
ty
. S
ta
te
 w
h
et
h
er
 t
h
e 
an
al
ys
is
 
w
as
 p
re
-s
pe
ci
fi
ed
. S
ta
te
 w
h
et
h
er
 a
n
y 
in
te
ra
ct
io
n
 i
s 
co
n
si
st
en
t 
ac
ro
ss
 t
ri
al
s.
 
P
ro
vi
de
 a
 d
es
cr
ip
ti
on
 o
f 
th
e 
di
re
ct
io
n
 a
n
d 
si
ze
 o
f 
ef
fe
ct
 i
n
 t
er
m
s 
m
ea
n
in
gf
u
l 
to
 t
h
os
e 
w
h
o 
w
ou
ld
 p
u
t 
fi
n
di
n
gs
 i
n
to
 p
ra
ct
ic
e.
R
is
k 
of
 b
ia
s 
22
P
re
se
n
t 
re
su
lt
s 
of
 a
n
y 
as
se
ss
m
en
t 
of
 r
is
k 
of
 b
ia
s 
re
la
ti
n
g 
to
 t
h
e 
ac
cu
m
u
la
te
d 
bo
dy
 o
f 
ev
id
en
ce
, i
n
cl
u
di
n
g 
an
y 
pe
rt
ai
n
in
g 
to
 
ac
ro
ss
 s
tu
di
es
th
e 
av
ai
la
bi
li
ty
 a
n
d 
re
pr
es
en
ta
ti
ve
n
es
s 
of
 a
va
il
ab
le
 s
tu
di
es
, o
u
tc
om
es
 o
r 
ot
h
er
 v
ar
ia
bl
es
.
co
nt
in
ue
s 
on
 t
he
 n
ex
t 
pa
ge
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impact OF patient GlObal assessment On lOnG-term radiOGraphic damaGe
c
o
n
t
In
u
A
t
Io
n
P
R
IS
M
A
-I
P
D
It
em
 
R
ep
or
te
d
 
Se
ct
io
n
/t
op
ic
N
o
C
h
ec
kl
is
t 
it
em
on
 p
ag
e
A
dd
it
io
n
al
 
23
G
iv
e 
re
su
lt
s 
of
 a
n
y 
ad
di
ti
on
al
 a
n
al
ys
es
 (
e.
g.
 s
en
si
ti
vi
ty
 a
n
al
ys
es
).
 I
f 
ap
pl
ic
ab
le
, t
h
is
 s
h
ou
ld
 a
ls
o 
in
cl
u
de
 a
n
y 
an
al
ys
es
 t
h
at
 
an
al
ys
es
in
co
rp
or
at
e 
ag
gr
eg
at
e 
da
ta
 f
or
 s
tu
di
es
 t
h
at
 d
o 
n
ot
 h
av
e 
IP
D
. I
f 
ap
pl
ic
ab
le
, s
u
m
m
ar
is
e 
th
e 
m
ai
n
 m
et
a-
an
al
ys
is
 r
es
u
lt
s 
fo
ll
ow
in
g
th
e 
in
cl
u
si
on
 o
r 
ex
cl
u
si
on
 o
f 
st
u
di
es
 f
or
 w
h
ic
h
 I
P
D
 w
er
e 
n
ot
 a
va
il
ab
le
.
D
is
cu
ss
io
n
Su
m
m
ar
y 
of
 
24
Su
m
m
ar
is
e 
th
e 
m
ai
n
 f
in
di
n
gs
, i
n
cl
u
di
n
g 
th
e 
st
re
n
gt
h
 o
f 
ev
id
en
ce
 f
or
 e
ac
h
 m
ai
n
 o
u
tc
om
e.
ev
id
en
ce
St
re
n
gt
h
s 
an
d 
25
D
is
cu
ss
 a
n
y 
im
po
rt
an
t 
st
re
n
gt
h
s 
an
d 
li
m
it
at
io
n
s 
of
 t
h
e 
ev
id
en
ce
 i
n
cl
u
di
n
g 
th
e 
be
n
ef
it
s 
of
 a
cc
es
s 
to
 I
P
D
 a
n
d 
an
y 
li
m
it
at
io
n
s 
li
m
it
at
io
n
s
ar
is
in
g 
fr
om
 I
P
D
 t
h
at
 w
er
e 
n
ot
 a
va
il
ab
le
.
C
on
cl
u
si
on
s
26
P
ro
vi
de
 a
 g
en
er
al
 i
n
te
rp
re
ta
ti
on
 o
f 
th
e 
fi
n
di
n
gs
 i
n
 t
h
e 
co
n
te
xt
 o
f 
ot
h
er
 e
vi
de
n
ce
.
Im
pl
ic
at
io
n
s
A
4
C
on
si
de
r 
re
le
va
n
ce
 t
o 
ke
y 
gr
ou
ps
 (
su
ch
 a
s 
po
li
cy
 m
ak
er
s,
 s
er
vi
ce
 p
ro
vi
de
rs
 a
n
d 
se
rv
ic
e 
u
se
rs
).
 C
on
si
de
r 
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impact OF patient GlObal assessment On lOnG-term radiOGraphic damaGe
APPEndIx 3. lIst of vArIAblEs rEquIrEd And dEsIrAblE for AnAlysEs
• Remission definition data (minimum at baseline, 6 and 12 months; desired also at 3 and 9 months, 2 years, others)
– SJC28 
– TJC28
– CRP (in mg/dl or mg/L, but clearly indicated)
– PGA
• Outcome data (minimum at baseline, 12 and 24 months; desired 5 and 10 years)
– Radiographic score
– HAQ
• Patient characteristics (all at baseline only)
– gender
– age at baseline
• Clinical characteristics (all at baseline only)
– disease duration at baseline
– RF
– ACPA (not essential)
– Treatment arm
• Trial/visit information
– anonymised patient ID code (at baseline only)
– visit number or sequence
– visit date
APPEndIx 4. ExAMPlEs of PAtIEnt's clAssIfIcAtIon In dIffErEnt rEMIssIon stAtE 
dEfInItIons (dIcHotoMIc And cAtEGorIcAl) And consIdErInG sInGlE or MultIPlE tIME 
PoInts (sustAInEd rEMIssIon) for Its AssEssMEnt
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